EGFR and neoplasm: Although there are human clinical trials ongoing on tumor imaging using anti-EGFR-antibodies labeled with diagnostic nuclides ([89Zr]Zr-cetuximab: NCT00691548 (completed), NCT01691391 (recruiting), [68Ga]Ga-EGFR-affibody: NCT02916329 (recruiting), [125I]I-MAB425: NCT01317888 (status unknown)) [17], none of these antibodies is FDA-approved yet, nor are they exploiting the full potency of radiolabeled antibodies in terms of therapeutic nuclides.